Ferric Citrate Patent Expiration
Ferric Citrate is Used for lowering and managing serum phosphorus levels. It was first introduced by Keryx Biopharmaceuticals Inc
Ferric Citrate Patents
Given below is the list of patents protecting Ferric Citrate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Auryxia | US10300039 | Ferric citrate dosage forms | Jul 21, 2030 | Keryx Biopharms |
| Auryxia | US9387191 | Ferric citrate dosage forms | Jul 21, 2030 | Keryx Biopharms |
| Auryxia | US8093423 | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same |
Apr 21, 2026
(Expired) | Keryx Biopharms |
| Auryxia | US7767851 | Ferric organic compounds, uses thereof and methods of making same |
Feb 18, 2024
(Expired) | Keryx Biopharms |
| Auryxia | US8299298 | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same |
Feb 18, 2024
(Expired) | Keryx Biopharms |
| Auryxia | US8338642 | Ferric organic compounds, uses thereof and methods of making same |
Feb 18, 2024
(Expired) | Keryx Biopharms |
| Auryxia | US8609896 | Ferric organic compounds, uses thereof and methods of making same |
Feb 18, 2024
(Expired) | Keryx Biopharms |
| Auryxia | US8754257 | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
Feb 18, 2024
(Expired) | Keryx Biopharms |
| Auryxia | US8754258 | Ferric organic compounds, uses thereof and methods of making same |
Feb 18, 2024
(Expired) | Keryx Biopharms |
| Auryxia | US8846976 | Ferric organic compounds, uses thereof and methods of making same |
Feb 18, 2024
(Expired) | Keryx Biopharms |
| Auryxia | US8901349 | Ferric organic compounds, uses thereof and methods of making same |
Feb 18, 2024
(Expired) | Keryx Biopharms |
| Auryxia | US9050316 | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
Feb 18, 2024
(Expired) | Keryx Biopharms |
| Auryxia | US9328133 | Ferric organic compounds, uses thereof and methods of making same |
Feb 18, 2024
(Expired) | Keryx Biopharms |
| Auryxia | US9757416 | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
Feb 18, 2024
(Expired) | Keryx Biopharms |
| Auryxia | US5753706 | Methods for treating renal failure |
Feb 03, 2022
(Expired) | Keryx Biopharms |
Ferric Citrate's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Ferric Citrate:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
| ||||
| Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease | Keryx Biopharmaceuticals | NA |
SUSPENDED
(Jun 1, 2026)
| PHASE3 |
| Ferric Citrate and Chronic Kidney Disease in Children | University of California, Los Angeles | NA |
RECRUITING
(Apr 1, 2026)
| PHASE2 |